Lv75
4000 积分 2024-04-15 加入
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
8个月前
已完结
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
8个月前
已完结
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
8个月前
已完结
First‐in‐human study with intratumoral administration of a CD40 agonistic antibody, ADC‐1013, in advanced solid malignancies
8个月前
已完结
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
8个月前
已完结
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
8个月前
已完结
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor
8个月前
已完结
Turning cold tumors hot: from molecular mechanisms to clinical applications
8个月前
已完结
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
8个月前
已完结
Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial
9个月前
已完结
皖公网安备34019202002308
